VA's McKesson Pharmaceutical Prime Vendor contract exceeds $1.1 billion, awarded via full and open competition

Contract Overview

Contract Amount: $1,110,402,104 ($1.1B)

Contractor: Mckesson Corporation

Awarding Agency: Department of Veterans Affairs

Start Date: 2025-12-01

End Date: 2025-12-31

Contract Duration: 30 days

Daily Burn Rate: $37.0M/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER

Place of Performance

Location: IRVING, DALLAS County, TEXAS, 75039

State: Texas Government Spending

Plain-Language Summary

Department of Veterans Affairs obligated $1.11 billion to MCKESSON CORPORATION for work described as: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER Key points: 1. The contract represents a significant portion of the VA's pharmaceutical spending, highlighting the scale of its drug procurement. 2. Full and open competition suggests a robust bidding process, potentially leading to competitive pricing. 3. The fixed-price contract type offers cost certainty for the government, mitigating risks associated with price fluctuations. 4. The contract's duration of 30 days for this specific delivery order indicates a need for rapid fulfillment of pharmaceutical needs. 5. McKesson's role as a prime vendor underscores its importance in the pharmaceutical supply chain for federal agencies. 6. The contract's value necessitates careful monitoring of performance and adherence to delivery schedules.

Value Assessment

Rating: good

The contract value of over $1.1 billion for a 30-day delivery order is substantial, reflecting the VA's large-scale pharmaceutical needs. Benchmarking against similar prime vendor contracts for federal agencies would provide further context on value for money. The firm fixed-price structure is a positive indicator for cost control. However, without specific performance metrics or detailed cost breakdowns, a definitive value assessment is challenging.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under full and open competition, indicating that multiple bidders were likely considered. This approach is generally favored as it allows for the widest possible pool of potential contractors, fostering a competitive environment. The number of bidders and the specifics of the bidding process would further illuminate the degree of competition and its impact on the final price.

Taxpayer Impact: Full and open competition is beneficial for taxpayers as it increases the likelihood of securing the best possible price and service through a competitive bidding process, preventing potential price gouging.

Public Impact

Veterans will benefit from timely access to a wide range of pharmaceuticals through the VA's healthcare system. The contract ensures the continuous supply of essential medications for medical treatment and health maintenance of veterans. Services are delivered nationwide, supporting VA medical centers and clinics across the United States. The contract supports jobs within McKesson Corporation's pharmaceutical distribution network, including logistics and administrative roles.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for over-reliance on a single prime vendor for a critical supply chain.
Ensuring consistent quality and availability of pharmaceuticals across all VA facilities.
Monitoring for any potential price increases in future contract renewals.
Managing the complexity of a large-value contract with a single awardee.

Positive Signals

Awarded through full and open competition, suggesting a competitive pricing environment.
Firm fixed-price contract provides cost certainty for the government.
McKesson's established track record as a major pharmaceutical distributor.
The contract ensures a reliable supply of pharmaceuticals for veterans' healthcare needs.

Sector Analysis

The pharmaceutical prime vendor market is a critical component of the healthcare sector, facilitating the distribution of medications from manufacturers to healthcare providers. Federal agencies, particularly the Department of Defense and the Department of Veterans Affairs, are significant purchasers of pharmaceuticals. This contract with McKesson represents a substantial portion of the VA's pharmaceutical spending, aligning with industry trends where large distributors play a pivotal role in managing complex supply chains and ensuring product availability.

Small Business Impact

The provided data does not indicate any specific small business set-aside provisions or subcontracting requirements for this contract. As a prime vendor contract of this magnitude, it is possible that McKesson may engage small businesses for specific logistical or support services, but this is not explicitly detailed. Further analysis would be needed to determine the extent of small business participation.

Oversight & Accountability

The Department of Veterans Affairs has established oversight mechanisms for its contracts, including performance monitoring and compliance checks. The Federal Acquisition Regulation (FAR) provides a framework for contract administration and accountability. Transparency is generally maintained through contract award databases, though detailed performance reports may not always be publicly accessible. The VA Office of Inspector General would have jurisdiction over any investigations into fraud, waste, or abuse related to this contract.

Related Government Programs

Department of Defense Pharmaceutical Prime Vendor Contracts
Federal Supply Schedule (FSS) Pharmaceutical Contracts
VA Medical Supplies and Equipment Procurement
National Acquisition Center (NAC) Contracts

Risk Flags

Potential for supply chain disruption
Price volatility in pharmaceutical markets
Contractor performance monitoring
Ensuring adequate competition in future procurements

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $1.11 billion to MCKESSON CORPORATION. EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER

Who is the contractor on this award?

The obligated recipient is MCKESSON CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $1.11 billion.

What is the period of performance?

Start: 2025-12-01. End: 2025-12-31.

What is McKesson Corporation's track record with the Department of Veterans Affairs and other federal agencies for pharmaceutical prime vendor services?

McKesson Corporation has a long-standing and extensive history of serving as a pharmaceutical prime vendor for the Department of Veterans Affairs (VA) and other federal agencies, including the Department of Defense. They are a major player in the pharmaceutical distribution landscape, consistently awarded large-scale contracts due to their established infrastructure, logistical capabilities, and broad product catalog. Their track record typically involves managing complex supply chains, ensuring timely delivery of a vast array of pharmaceuticals, and adhering to stringent regulatory requirements. While generally considered reliable, like any large contractor, they may have faced scrutiny or performance issues on specific contracts over time, which would be detailed in contract performance reports and agency evaluations. Their continued success in securing prime vendor contracts suggests a generally positive performance history and a strong competitive position within the federal pharmaceutical procurement space.

How does the value of this specific delivery order compare to the overall annual pharmaceutical spending of the VA?

This specific delivery order, valued at approximately $1.11 billion, represents a significant portion of the VA's pharmaceutical procurement. While the exact annual pharmaceutical spending for the VA fluctuates, it typically runs into several billion dollars each fiscal year. For context, the VA's total pharmaceutical spending has historically been in the range of $4-6 billion annually. Therefore, this single delivery order, covering a 30-day period, is exceptionally large and likely encompasses a substantial volume of critical medications. It suggests either a very high demand during this period or that this order represents a significant portion of the VA's contracted pharmaceutical needs for a given timeframe, possibly covering a large contract period or a specific high-volume procurement event.

What are the primary risks associated with a single, large prime vendor contract for pharmaceutical distribution?

A primary risk associated with a single, large prime vendor contract for pharmaceutical distribution is the potential for over-reliance on one entity. This can create vulnerabilities in the supply chain; if the prime vendor experiences disruptions (e.g., logistical failures, labor disputes, cyberattacks, or financial instability), it could significantly impact the availability of essential medications for the agency. Another risk is reduced price competition over time, as the incumbent vendor may have an advantage in future re-procurements. Furthermore, a single large contract might limit the agency's flexibility to adapt to rapidly changing market conditions or to incorporate innovative distribution solutions from smaller, specialized providers. Ensuring robust performance standards, contingency planning, and strong oversight are crucial to mitigate these risks.

What does the 'Pharmaceutical Preparation Manufacturing' (NAICS 325412) classification imply for this contract?

The NAICS code 325412, 'Pharmaceutical Preparation Manufacturing,' indicates the industry classification related to the production of pharmaceutical preparations. While this contract is for a 'Pharmaceutical Prime Vendor,' which primarily involves distribution and logistics, the NAICS code might be assigned based on the primary business activity of the awarded contractor, McKesson Corporation. McKesson is a major pharmaceutical distributor but also engages in related activities that could fall under this manufacturing umbrella, such as packaging, compounding, or specific formulation services, depending on the contract's scope. For this specific contract, it suggests the VA is procuring pharmaceutical products that are either manufactured or prepared by the contractor or sourced through their manufacturing-related supply chain, ensuring compliance with manufacturing standards even if the primary service is distribution.

How does the 'Delivery Order' (AW) type affect the contract's structure and the government's flexibility?

A 'Delivery Order' (AW) is typically issued against an existing indefinite-delivery, indefinite-quantity (IDIQ) contract or a similar type of contract that establishes terms and conditions for future purchases. This means the overarching contract (which might be a longer-term agreement) sets the framework, and the delivery order specifies the exact quantity, delivery date, and price for a particular shipment or period. For the government, this structure offers flexibility; they can order what they need, when they need it, up to the contract's maximum value. It allows for adapting to fluctuating demand. For the contractor, it provides a commitment for potential business but requires them to be ready to fulfill orders as they are placed. The short 30-day duration of this specific delivery order suggests it's for immediate or near-term needs.

What is the significance of the 'FIRM FIXED PRICE' (PT) contract type in this context?

The 'FIRM FIXED PRICE' (PT) contract type is significant because it establishes a ceiling price that the contractor must not exceed, and the government is obligated to pay the negotiated price regardless of the contractor's actual costs. This provides the government with maximum price certainty and cost control, as the financial risk of cost overruns is borne entirely by the contractor. For a large-volume procurement like pharmaceuticals, where costs can be influenced by market fluctuations, a firm fixed price helps protect the agency's budget. It incentivizes the contractor to manage their costs efficiently to maintain profitability. This contract type is generally preferred when the scope of work is well-defined and risks are understood.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 6555 STATE HIGHWAY 161, IRVING, TX, 75039

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $1,110,402,104

Exercised Options: $1,110,402,104

Current Obligation: $1,110,402,104

Contract Characteristics

Multi-Year Contract: Yes

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 36W79720D0001

IDV Type: IDC

Timeline